Skip to main content
Year archive

Xbrane Biopharma — 2022 filings

All 41 regulatory filings released by Xbrane Biopharma (XBRANE) in 2022, sourced directly from the official regulator.

41 Filings
2022 Period
2022 filings (41)
Filing Released Lang
XBRANE PROVIDES AN UPDATE ON RANIBIZUMAB BIOSIMILAR CANDIDATE FDA FILING
Regulatory Filings
2022-12-15 English
XBRANE UPPDATERAR OM ANSÖKAN AVSEENDE MARKNADSGODKÄNNANDE TILL FDA FÖR SIN RANIBIZUMAB BIOSIMILARKANDIDAT
Regulatory Filings
2022-12-15 Swedish
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
Regulatory Filings
2022-11-11 English
STADA och Xbrane erhåller EU-godkännande för Ximluci® (ranibizumab) biosimilar till referensläkemedlet Lucentis®
Regulatory Filings
2022-11-11 Swedish
Förändrat antal aktier och röster i Xbrane
Share Issue/Capital Change
2022-10-31 Swedish
Change of number of shares and votes in Xbrane
Declaration of Voting Results & Voting Rights Announcements
2022-10-31 English
Earnings Release 2022
Earnings Release 9M 2022
2022-10-28 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report 9M 2022
2022-10-28 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-10-21 English
Xbrane Biopharma presents Nomination Committee
AGM Information
2022-10-20 English
Xbrane Biopharma presenterar valberedning
Board/Management Information
2022-10-20 Swedish
Xbrane has carried out a directed share issue raising gross proceeds of approximately SEK 170 million
Capital/Financing Update
2022-10-18 English
Xbrane Biopharma har genomfört en riktad nyemission och tillförs därigenom cirka 170 miljoner kronor
Share Issue/Capital Change
2022-10-18 Swedish
Xbrane Biopharma offentliggör avsikt att genomföra en riktad nyemission
Capital/Financing Update
2022-10-18 Swedish
Xbrane announces intention to carry out a directed share issue
Capital/Financing Update
2022-10-18 English
STADA and Xbrane welcome EMA positive opinion for ranibizumab biosimilar candidate Ximluci
Regulatory Filings
2022-09-16 English
STADA och Xbrane välkomnar EMA:s positiva utlåtande för ranibizumab biosimilarkandidaten Ximluci
Regulatory Filings
2022-09-16 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q2 2022
2022-07-22 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q2 2022
2022-07-22 English
Xbrane provides update on ranibizumab biosimilar candidate FDA filing
Regulatory Filings
2022-07-04 English
Xbrane uppdaterar om ansökan avseende marknadsgodkännande till FDA för sin ranibizumab biosimilarkandidat
Report Publication Announcement
2022-07-04 Swedish
Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company.
Declaration of Voting Results & Voting Rights Announcements
2022-06-30 English
Xbrane Biopharma AB ("Xbrane" eller "Bolaget") meddelar om förändring av antalet aktier och röster i Bolaget.
Share Issue/Capital Change
2022-06-30 Swedish
Xbrane provides update on ranibizumab biosimilar candidate FDA filing
Regulatory Filings
2022-05-30 English
Xbrane uppdaterar om ansökan avseende marknadsgodkännande till FDA för sin ranibizumab biosimilar kandidat
Report Publication Announcement
2022-05-30 Swedish
Kommuniké från årsstämman i Xbrane Biopharma
AGM Information
2022-05-05 Swedish
Announcement from Xbrane Biopharma's annual general meeting
AGM Information
2022-05-05 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Q1 2022
2022-05-05 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q1 2022
2022-05-05 English
Notice of annual general meeting in Xbrane Biopharma AB
AGM Information
2022-04-04 English
Kallelse till årsstämma i Xbrane Biopharma AB
AGM Information
2022-04-04 Swedish
Annual Report 2021
Annual Report FY 2021
2022-03-31 Swedish
Annual Report 2021
Annual Report FY 2021
2022-03-31 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q4 2021
2022-02-24 Swedish
Earnings Release 2021
Earnings Release FY 2021
2022-02-24 English
Xbrane ger en uppdatering om sitt dotterbolag Primm Pharma
Regulatory Filings
2022-02-17 Swedish
Xbrane provides an update on its subsidiary Primm Pharma
M&A Activity
2022-02-17 English
Xbrane announces positive top-line results from the pivotal phase III equivalence trial for Xlucane™ - a biosimilar candidate to Lucentis®
Regulatory Filings
2022-02-15 English
Xbrane tillkännager positiva top-line resultat från den registreringsgrundande fas III ekvivalensstudien med Xlucane™ – en biosimilarkandidat till Lucentis®
Regulatory Filings
2022-02-15 Swedish
Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
Regulatory Filings
2022-02-07 English
Biogen och Xbrane tillkännager kommersialiserings- och licensavtal för en biosimilarkandidat till CIMZIA® (Certolizumab pegol) med potential att behandla ledgångsreumatism
Regulatory Filings
2022-02-07 Swedish